Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.60
-0.41 (-1.58%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Mineralys Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,2632,872613354--
Market Cap Growth
124.45%368.78%73.31%---
Enterprise Value
1,6992,278349100--
Last Close Price
25.6036.2912.318.60--

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
4.114.443.201.47--
P/TBV Ratio
4.114.443.201.47--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Debt / Equity Ratio
-1.02-1.01-1.04-0.98-1.03-1.75
Net Debt / EBITDA Ratio
1.523.851.03---
Net Debt / FCF Ratio
4.064.611.192.913.770.73
Quick Ratio
34.2443.4513.5322.5713.652.10
Current Ratio
34.4643.7614.0223.7713.982.20
Return on Equity (ROE)
-80.88%-36.91%-82.24%-41.38%-53.00%-1568.96%
Return on Assets (ROA)
-46.18%-24.58%-52.56%-28.91%-31.34%-185.60%
Return on Capital Employed (ROCE)
-57.20%-26.40%-100.60%-35.10%-29.60%-308.40%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-15.45%-5.38%-29.02%-20.34%--
FCF Yield
-6.13%-4.96%-27.16%-22.96%--
Buyback Yield / Dilution
-46.24%-39.38%-34.13%-600.33%-3.67%-7.64%
SEC Filings: 10-K · 10-Q